Merck Serono related Press Releases
NICE Recommends Use Of Cetuximab (Erbitux(R)) For UK Bowel Cancer Patients
NICE Recommends Use Of Cetuximab (Erbitux(R)) For UK Bowel Cancer Patients The National Institute for Health and Clinical Excellence (NICE) has today published a Final Appraisal Determination (FAD)... Read more...
Results at ASCO Congress 2009 Highlight Merck Serono's Leadership in Personalizing Cancer Care
Results at ASCO Congress 2009 Highlight Merck Serono's Leadership in Personalizing Cancer Care
70 abstracts accepted for inclusion in the ASCO annual meeting
DARMSTADT, Germany--(BUSINESS
Merck Serono Launches Glucophage(R) Powder (Metformin Hydrochloride) in First European Countries
Merck Serono Launches Glucophage(R) Powder (Metformin Hydrochloride) in First European Countries - Innovative Powder Formulation of Metformin Designed to Facilitate Adherence by Increasing Patient
... Read more...Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA,
... Read more...Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial GENEVA, Switzerland, January 23
... Read more...Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis - Merck Serono and Apitope to Collaborate on Development and
... Read more...Merck Serono and Apitope Technology Announce Licensing Agreement on Novel Peptide Therapeutics
Merck Serono and Apitope Technology Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis; Apitope Eligible to Receive up to EUR 154 Million GENEVA,
... Read more...Merck Serono: Study Published in JCO Shows Erbitux Enhances Efficacy in mCRC Patients with KRAS Wild-Type Tumors in 1st-Line Set
Merck Serono: Study Published in JCO Shows Erbitux Enhances Efficacy in mCRC Patients with KRAS Wild-Type Tumors in 1st-Line Setting ·Results of OPUS trial support new standard of care for
... Read more...Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe
Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe GENEVA, Switzerland, December 9 /PRNewswire/ -- - First Drug to be Approved in Europe for the Treatment of Hyperphenylalaninemia due
... Read more...Galapagos NV and Merck Serono Enter New Collaboration Agreements
Galapagos NV and Merck Serono Enter New Collaboration Agreements MECHELEN, BELGIUM--(MARKET WIRE)--Nov 18, 2008 -- Galapagos NV (Euronext: GLPG) announced today new collaboration agreements with
... Read more...Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
